News Image

Exploring NYSE:WST's dividend characteristics.

By Mill Chart

Last update: Mar 22, 2024

Our stock screener has spotted WEST PHARMACEUTICAL SERVICES (NYSE:WST) as a good dividend stock with solid fundamentals. NYSE:WST shows decent health and profitability. At the same time it gives a good and sustainable dividend. We'll dive into each aspect below.

Exploring NYSE:WST's Dividend

ChartMill assigns a proprietary Dividend Rating to each stock. The score is computed by evaluating various valuation aspects, like the yield, the history, the dividend growth and sustainability. NYSE:WST was assigned a score of 7 for dividend:

  • WST's Dividend Yield is rather good when compared to the industry average which is at 0.63. WST pays more dividend than 86.44% of the companies in the same industry.
  • The dividend of WST is nicely growing with an annual growth rate of 6.31%!
  • WST has paid a dividend for at least 10 years, which is a reliable track record.
  • WST has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
  • WST pays out 9.61% of its income as dividend. This is a sustainable payout ratio.
  • The dividend of WST is growing, but earnings are growing more, so the dividend growth is sustainable.

Understanding NYSE:WST's Health Score

ChartMill assigns a Health Rating to every stock. This score ranges from 0 to 10 and evaluates the different health aspects like liquidity and solvency, both absolutely, but also relative to the industry peers. NYSE:WST scores a 8 out of 10:

  • An Altman-Z score of 21.40 indicates that WST is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of WST (21.40) is better than 98.31% of its industry peers.
  • The Debt to FCF ratio of WST is 0.50, which is an excellent value as it means it would take WST, only 0.50 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of WST (0.50) is better than 94.92% of its industry peers.
  • A Debt/Equity ratio of 0.03 indicates that WST is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.03, WST is in the better half of the industry, outperforming 62.71% of the companies in the same industry.
  • A Current Ratio of 2.88 indicates that WST has no problem at all paying its short term obligations.
  • WST has a Quick Ratio of 2.24. This indicates that WST is financially healthy and has no problem in meeting its short term obligations.

Assessing Profitability for NYSE:WST

ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NYSE:WST, the assigned 9 is a significant indicator of profitability:

  • The Return On Assets of WST (15.50%) is better than 94.92% of its industry peers.
  • WST has a Return On Equity of 20.60%. This is amongst the best in the industry. WST outperforms 93.22% of its industry peers.
  • WST has a better Return On Invested Capital (18.40%) than 96.61% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for WST is significantly above the industry average of 10.03%.
  • WST has a Profit Margin of 20.12%. This is amongst the best in the industry. WST outperforms 94.92% of its industry peers.
  • In the last couple of years the Profit Margin of WST has grown nicely.
  • WST has a Operating Margin of 23.90%. This is amongst the best in the industry. WST outperforms 93.22% of its industry peers.
  • WST's Operating Margin has improved in the last couple of years.
  • WST's Gross Margin has improved in the last couple of years.

More Best Dividend stocks can be found in our Best Dividend screener.

Check the latest full fundamental report of WST for a complete fundamental analysis.

Keep in mind

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

WEST PHARMACEUTICAL SERVICES

NYSE:WST (4/18/2024, 7:04:00 PM)

After market: 377.33 0 (0%)

377.33

-0.03 (-0.01%)

WST News

News Image7 days ago - ChartmillWhy the dividend investor may take a look at NYSE:WST.

Is WEST PHARMACEUTICAL SERVICES (NYSE:WST) a Good Fit for Dividend Investing?

News Image8 days ago - West Pharmaceutical Services, Inc.West to Host First-Quarter 2024 Conference Call

/PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced...

News Image16 days ago - Market News VideoMettler-Toledo International Takes Over #284 Spot From West Pharmaceutical Services
News Imagea month ago - Market News VideoFriday Sector Laggards: Technology & Communications, Healthcare
News Imagea month ago - InvestorPlace3 Pharma Stocks to Sell in March Before They Crash & Burn

Discover top pharma stocks to sell in March before they plummet. Learn why ACAD, AMLX and WST are on the list for urgent sell-off decisions.

News Imagea month ago - Market News VideoMay 17th Options Now Available For West Pharmaceutical Services (WST)
News Image2 months ago - West Pharmaceutical Services, Inc.West to Participate in Upcoming Investor Conferences

/PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced...

News Image2 months ago - Seeking AlphaWest Pharmaceutical declares $0.20 dividend (NYSE:WST)

West Pharmaceutical (WST) declares $0.20/share quarterly dividend, in line with previous. Forward yield 0.22% Payable May 1; for shareholders of record April 24

News Image2 months ago - West Pharmaceutical Services, Inc.West Announces Second-Quarter 2024 Dividend

/PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today...

News Image2 months ago - BusinessInsiderWest Pharmaceutical's 2024 Outlook Cautious, Analysts Remain Optimistic

West Pharmaceutical Services reports Q4 2023 adjusted EPS at $1.83, surpassing consensus. Quarterly sales hit $732 million missing estimates. 2024 guidance hints at moderated organic growth, emphasizing inventory management strategies.

News Image2 months ago - Market News VideoNoteworthy Thursday Option Activity: WST, LULU, UPS
News Image2 months ago - Market News VideoS&P 500 Movers: WST, ZBRA
WST Links
Follow us for more